ZZ6398
Schizophrenia
Phase 1/2Active
Key Facts
About Zhongze Therapeutics
Clinical-stage biotech developing next-generation antipsychotics, with lead candidate ZZ6398 targeting schizophrenia and depression.
View full company profileAbout Zhongze Therapeutics
Clinical-stage biotech developing next-generation antipsychotics, with lead candidate ZZ6398 targeting schizophrenia and depression.
View full company profileTherapeutic Areas
Other Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| DB103 (Pomaglumetad) | Denovo Biopharma | Phase 2b/3 |
| RBP-7000 (PERSERIS®) | Indivior | Marketed |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| Schizophrenia Candidate | Teva | Phase 3 |
| Schizophrenia Model Service | NeuroProof | Pre-clinical |
| LYN-005 (Nortiva) | Lyndra | Phase 3 |
| TerXT | Terran Biosciences | Late-stage (Pre-Phase 3) |
| Undisclosed Program | Curemark | Preclinical |
| Schizophrenia Intermediate | OFD Biopharma | Proof of concept |
| Schizophrenia | Keltic Pharma Therapeutics | Pre-clinical |
| AVAT-031 | Avata Biosciences | Discovery |
| Risperidone Implant | Delpor | Phase 1b/2a / Late-stage |